deltatrials

Post-essential thrombocythemia myelofibrosis Trials in Cleveland, United States

Conditions / Post-essential thrombocythemia myelofibrosis / Cleveland, United States

Post-essential thrombocythemia myelofibrosis is a medical condition with active clinical research programs worldwide.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT04884191 Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib COMPLETED PHASE2
NCT04551053 To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) TERMINATED PHASE3
NCT03165734 A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis ACTIVE_NOT_RECRUITING
NCT05467800 Study of Canakinumab in Patients With Myelofibrosis RECRUITING PHASE2
NCT04173494 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) COMPLETED PHASE3
NCT02124746 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia COMPLETED PHASE2
NCT05320198 Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia RECRUITING
NCT02055781 Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia TERMINATED PHASE3
NCT04603495 Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) ACTIVE_NOT_RECRUITING PHASE3
NCT03373877 Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis TERMINATED PHASE1

Related Pages